



HAL
open science

Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death

Inmaculada Posadas, Laura Romero-Castillo, Rosa-Anna Ronca, Andrii Karpus, Serge Mignani, Jean-Pierre Majoral, Mariángeles Muñoz-Fernández, Valentín Ceña

► **To cite this version:**

Inmaculada Posadas, Laura Romero-Castillo, Rosa-Anna Ronca, Andrii Karpus, Serge Mignani, et al.. Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death. *International Journal of Molecular Sciences*, 2022, 23 (8), pp.4391. 10.3390/ijms23084391 . hal-03659072

HAL Id: hal-03659072

<https://hal.science/hal-03659072v1>

Submitted on 4 May 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Article

Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death

Inmaculada Posadas^{1,2}, Laura Romero-Castillo¹ , Rosa-Anna Ronca¹, Andrii Karpus³, Serge Mignani^{4,5}, Jean-Pierre Majoral³, Mariángeles Muñoz-Fernández⁶ and Valentín Ceña^{1,2,*}

¹ Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La Mancha, 02006 Albacete, Spain; inmaculada.posadas@uclm.es (I.P.); laura.romero.castillo@ki.se (L.R.-C.); ros-anna88@hotmail.it (R.-A.R.)

² Centro de Investigación Biomédica en Red (CIBER), Instituto de Salud Carlos III (ISCIII), 20029 Madrid, Spain

³ Laboratoire de Chimie de Coordination (LCC), Centre National de la Recherche Scientifique (CNRS), 31400 Toulouse, France; andrii.karpus@lcc-toulouse.fr (A.K.); jean-pierre.majoral@lcc-toulouse.fr (J.-P.M.)

⁴ Department Medicinal Chemistry, Université Paris Descartes, 75006 Paris, France; serge_mignani@orange.fr

⁵ Centro de Química da Madeira, Universidade da Madeira, 9000-072 Funchal, Portugal

⁶ Department of Immunology, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; mmunoz.hgugm@gmail.com

* Correspondence: valentin.cena@uclm.es or valentin.cena@gmail.com

Abstract: Nanoparticles are playing an increasing role in biomedical applications. Excitotoxicity plays a significant role in the pathophysiology of neurodegenerative diseases, such as Alzheimer's or Parkinson's disease. Glutamate ionotropic receptors, mainly those activated by N-methyl-D-aspartate (NMDA), play a key role in excitotoxic death by increasing intraneuronal calcium levels; triggering mitochondrial potential collapse; increasing free radicals; activating caspases 3, 9, and 12; and inducing endoplasmic reticulum stress. Neutral phosphorous dendrimers, acting intracellularly, have neuroprotective actions by interfering with NMDA-mediated excitotoxic mechanisms in rat cortical neurons. In addition, phosphorous dendrimers can access neurons inside human brain organoids, complex tridimensional structures that replicate a significant number of properties of the human brain, to interfere with NMDA-induced mechanisms of neuronal death. Phosphorous dendrimers are one of the few nanoparticles able to gain access to the inside of neurons, both in primary cultures and in brain organoids, and to exert pharmacological actions by themselves.

Keywords: phosphorous dendrimers; excitotoxicity; cortical neurons; brain organoids; neuroprotection; mitochondria



Citation: Posadas, I.;

Romero-Castillo, L.; Ronca, R.-A.; Karpus, A.; Mignani, S.; Majoral, J.-P.; Muñoz-Fernández, M.; Ceña, V.

Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death. *Int. J. Mol. Sci.* **2022**, *23*, 4391. <https://doi.org/10.3390/ijms23084391>

Academic Editor: Antonio Pisani

Received: 9 March 2022

Accepted: 13 April 2022

Published: 15 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

In nanomedicine, engineered nanoparticles (NPs) have sparked a rapidly growing interest for diverse biomedical applications, including their use as delivery platforms (nanocarriers) for drugs or nucleic acids [1]. NPs have revolutionized research and changed our current concept of therapeutics and diagnostics. Some of these NPs have been used in clinical trials to deliver therapeutic compounds to treat diverse diseases, such as hereditary transthyretin amyloidosis [2] and acute intermittent porphyria [3]. In addition, some of them are key elements to vehiculate mRNA-based COVID-19 vaccines [4]. However, there is a group of diseases, neurodegenerative diseases, where NPs are still far from contributing to an efficient therapeutic approach. Neurodegenerative diseases, including, among others, Alzheimer's and Parkinson's disease, have an increasing incidence in the population due to increased life expectation [5]. This lack of NP efficiency can be due to the difficulty NPs face in crossing the blood–brain barrier (BBB) that stands between the blood stream and the brain parenchyma, strongly limiting the passage of foreign substances, such as drugs and NPs, into the brain [6] and/or contributing to the difficulty for NPs to enter non-dividing cells, such as neurons, once they are inside the brain.

Different NP types have been proposed for a broad range of biomedical applications [7,8]. Dendrimers are well-defined, nano-sized, homogeneous, monodisperse structures consisting of (1) a central core that allows various branch-type linkages, which are composed of repeated units leading to a series of radially concentric layers named generations (G), and (2) terminal functional groups that facilitate interactions with molecules of biological interests [9]. Dendrimers allow more specific drug targeting and delivery of small drugs [10] or siRNA [11] to different cell types. One specific class of dendrimers, phosphorous dendrimers, has shown several noteworthy biological activities, including anti-inflammatory [12], anti-prion [13], and anti-cancer [14] effects both in vitro and in vivo.

Organoids are tridimensional structures that can be generated from stem cells or from induced pluripotent progenitor cells [15]. Organoids are not complete organs but representative parts of the original organs reproducing some of their structural, molecular, and functional characteristics [16,17]. Brain organoids have a 3D structure much closer to the human brain than that found in laboratory animals, allowing more precise and reliable studies than those involving laboratory animals or primary neuronal cultures [18]. This similarity, together with the human origin of the cells used to generate them, makes brain organoids suitable models for reproducing the behavior of the human brain in models of human pathology, such as neurodegenerative diseases [19], providing results that can be less prone to fail in future clinical trials.

Glutamate is the main excitatory neurotransmitter in the central nervous system (CNS) playing a central role in neuronal plasticity, learning, and memory [20]. However, when extracellular glutamate concentration increases to levels above physiological levels, it causes aberrant synaptic signaling, which leads to excitotoxicity and neuronal death [21]. Excitotoxicity is a common mechanism causing neuronal damage in different human diseases, such as stroke, nervous system trauma, epilepsy, and chronic neurodegenerative disorders, including Parkinson's and Alzheimer's disease [22]. Excitotoxicity causes neuronal death by over-stimulation of ionotropic glutamate receptors, the N-methyl-D-aspartate receptor (NMDAR) being the main glutamate receptor subtype involved in excitotoxicity [23]. NMDAR over-stimulation increases intracellular Ca^{2+} concentrations ($[\text{Ca}^{2+}]_i$), leading to mitochondrial dysfunction, which is characterized by a decrease in mitochondrial potential (Ψ_m); increase in reactive oxygen species (ROS) production; electron transport chain dysfunction; decrease in ATP production; and release of pro-apoptotic factors, including cytochrome c and apoptotic protease activating factor 1 (Apaf-1), leading to sequential activation of caspases 9 and 3 [24].

In addition to high- Ca^{2+} -mediated mitochondrial mechanisms, excitotoxicity triggers endoplasmic reticulum (ER)- Ca^{2+} homeostasis disruption [25], which can contribute to neuronal cell death through two main pathways. On the one hand, it can induce an apoptosis crosstalk between both organelles followed by the mitochondria-mediated toxicity events mentioned above [26]. On the other hand, impairment of ER functioning triggers the activation of the unfolded protein response (UPR), leading to a shutdown of translation and an over-expression of ER-stress-related proteins [27]. Prolonged UPR activation also induces cell death by activating, among others, proteins-like eukaryotic initiation factor 2 α (eIF2 α), immunoglobulin heavy-chain-binding protein (GRP78/Bip), activator transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), and caspase 12, which are major components of ER-stress-induced apoptosis [28]. It is important to note that the inhibition of Ca^{2+} release from the ER protects cortical neurons against NMDA-induced excitotoxicity by attenuating both mitochondrial damage and ER stress [29].

In addition to an increase in $[\text{Ca}^{2+}]_i$, mitochondrial dysfunction, and ER stress, excitotoxicity generates an inflammatory response [30]. Thus, we decided to study the effect of neutral phosphorous dendrimers of generations 3 and 4 (Figure S1) that have previously displayed a marked anti-inflammatory action [12], both in vitro and in vivo, on a well-established in vitro model of excitotoxicity such as NMDA-mediated toxicity both in primary mouse cortical neurons [21] and in human brain organoids.

We found that both phosphorous dendrimer generations markedly decreased NMDA-mediated excitotoxicity in primary cortical neurons by an action downstream from NMDA-mediated Ca^{2+} entry that involves decreased production of mitochondrial ROS, ER stress, and UPR responses. The dendrimers also showed a marked neuroprotective action in NMDA-treated human brain organoids by decreasing NMDA-induced caspase 3, 9, and 12 activation as well as neuronal death. These data strongly suggest that neutral phosphorous dendrimers can penetrate not only neurons in culture but also a 3D structure, such as the brain organoid, and that this family of dendrimers might represent a useful scaffold to design new NP-based therapeutic agents for treating neurodegenerative diseases.

2. Results

2.1. Effect of Phosphorous Dendrimers on Excitotoxicity

To study the effect of G3 and G4 phosphorous dendrimers on NMDA-induced neuronal death, mouse cortical neurons were treated with vehicle or NMDA (150 μM ; 24 h) in the presence or absence of phosphorous dendrimers (1 to 10 μM). As expected, NMDA induced a significant increase in the LDH released, which amounted to about 37% of the total LDH content. Both phosphorous dendrimer generations, G3 and G4, markedly decreased NMDA-induced neuronal death in a concentration-dependent manner, G3 being slightly more potent than G4. At the maximal concentration studied (10 μM), both phosphorous dendrimer generations almost halved NMDA-induced neuronal death (Figure 1).




Figure 1. Phosphorous dendrimers prevent NMDA-mediated excitotoxicity. Neurons were treated with the indicated concentration of phosphorous dendrimers G3 (open circles), G4 (closed circles), or MnTBAP (10 μM ; closed triangle) for 1 h; and then NMDA (150 μM) was added and incubation continued for another 24 h. LDH activity was determined as indicated in the Materials and Methods section. Zero concentration represents net (stimulated–basal) NMDA-induced LDH release in the absence of any other treatment. The data represent the mean \pm the s.e.m. of 6 to 12 independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ when compared to NMDA-treated cells.

2.2. Phosphorous Dendrimers Lack Any Effect on an NMDA-Induced Increase in $[\text{Ca}^{2+}]_i$

Phosphorous dendrimers might decrease NMDA-mediated excitotoxic neuronal death by interfering with NMDA-induced increase in $[\text{Ca}^{2+}]_i$, which is related to neuronal death [31]. Treatment of cortical neurons with NMDA (150 μM) induced almost a 40% increase in $[\text{Ca}^{2+}]_i$, which was not modified by the presence of phosphorous dendrimers (Figure 2 and Figure S2), suggesting that the dendrimers did not exert their neuroprotective effect interfering with NMDA receptor activation and that the protective effect was mediated by an intracellular action.




Figure 2. Effect of phosphorous dendrimers on NMDA-induced increase in $[Ca^{2+}]_i$. Neurons were treated (10 μ M; 1 h) with G3 or G4 phosphorous dendrimers. Then, the neurons were incubated with Fura-2 and exposed to NMDA (150 μ M) in the absence (V) and presence of dendrimers. Data represent the percentage over basal line (100%) of the ratio of fluorescence taken as an index of $[Ca^{2+}]_i$, as indicated in the Materials and Methods section. The data are expressed as the mean + the s.e.m. of 30 to 40 neurons obtained from three independent experiments.

2.3. Phosphorous Dendrimers Decrease NMDA-Induced ROS Production

Next, we explored if the phosphorous dendrimers were acting at the mitochondrial level to prevent excitotoxicity. NMDA-induced Ca^{2+} overload has been related to a decrease in Ψ_m leading to an increase in ROS production and the activation of the intrinsic apoptotic pathway [32]. Exposure of mouse cortical neurons to NMDA (150 μ M) induced a fast decrease in Ψ_m to about 40% of control values at 1 h (Figure S3a), which was followed by an increase in both mitochondrial (Figure S3b) and total ROS (Figure S3c) production. Both phosphorous dendrimer generations, G3 and G4, were able to partially prevent NMDA-induced decrease in Ψ_m (Figure 3a) and, accordingly, almost halved NMDA-induced mitochondrial (Figure 3b) and total ROS (Figure 3c) production. One possible explanation is that phosphorous dendrimers would be acting as antioxidant agents by either inhibiting ROS production or scavenging the produced ROS. As indicated in Figure S4, this is not the case since the generation of phosphorous dendrimers did not inhibit xanthine-oxidase-mediated superoxide generation either in a cell-free system or in lysates of both cortical neurons and brain organoids, while the superoxide dismutase (SOD) cell-permeant mimetic Mn(III)tetrakis (4-benzoic acid)porphyrin chloride (MnTABP) inhibited by more than 50% superoxide production (Figure S4).




Figure 3. Cont.




Figure 3. Effect of G3 and G4 phosphorous dendrimers on NMDA-induced changes in Ψ_m and ROS levels. Neurons were treated with vehicle (V), G3, or G4 phosphorous dendrimers (10 μ M) for 1 h, and then NMDA (150 μ M) was added. Neuronal (a) mitochondria potential, (b) mitochondrial ROS, and (c) total cellular ROS were determined as indicated in the Materials and Methods section. The data are expressed as the mean + the s.e.m. of 30 to 40 neurons obtained from four independent experiments. *** $p < 0.001$ as compared to NMDA-treated cells in the absence of dendrimers.

2.4. Phosphorous Dendrimers Inhibit NMDA-Induced Intrinsic Apoptotic Pathway Activation

Loss of Ψ_m has been related to caspase activation and induction of the intrinsic apoptotic pathway [33]. Thus, we studied the effect of phosphorous dendrimers on NMDA-mediated activation of caspases 9 and 3. Treatment of mouse cortical neurons with NMDA resulted in an early activation of caspase 9, coinciding with the loss of mitochondrial membrane potential (Figure S5a). Caspase 9 activation was followed by caspase 3 activation, which reached maximal activity at 3 h (Figure S5b). Lengths of time for maximal NMDA-induced caspase 3 and 9 activation were selected for the next experiments. Both phosphorous dendrimer generations reduced NMDA-induced caspase 9 (Figure 4a) and 3 (Figure 4b) enzymatic activity in a dose-dependent manner. This suggests that, at least in part, the neuroprotective effect of these phosphorous dendrimers was related to an inhibition of the intrinsic apoptotic pathway.




Figure 4. Effect of G3 and G4 phosphorous dendrimers on NMDA-induced (a) caspase 9 and (b) caspase 3 activities. Neurons were treated with vehicle (V) or the indicated concentration of G3 or G4 phosphorous dendrimers. Then, NMDA (150 μ M) was added and incubation continued for 3 h. Caspase activity was determined in total lysates as described in the Materials and Methods section. The data are expressed as the mean + the s.e.m. of three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ as compared to NMDA-treated cells in the absence of dendrimers.

2.5. Phosphorous Dendrimers Inhibit NMDA-Induced Activation of the ER Stress Pathway

Endoplasmic reticulum stress has been linked to excitotoxic neuronal death in several neurodegenerative disorders since it promotes mitochondrial dysfunction and induces specific ER stress and apoptosis pathways [29]. Next, we decided to explore whether phosphorous dendrimers were interfering with the ER stress response. First, we observed that NMDA (150 μ M) induced the activation of the ER stress response, characterized by an

initial and transitory increase in eIF2 α phosphorylation (p-eIF2 α), without modifying total levels of eIF2 α total protein (Figure S6a; Table S1). In addition, increases in Bip, ATF4, and Chop proteins were observed at longer lengths of time (Figure S6a; Table S1), consistent with an ER stress response activation. Both generations of phosphorous dendrimers prevented NMDA-induced increase in p-eIF2 α phosphorylation (Figures 5a and 6a) and significantly reduced NMDA-induced increase in Bip (Figures 5a and 6b) and CHOP (Figures 5a and 6c) protein levels. NMDA also induced caspase 12 activation peaking at 6 h (Figure S5b), which was almost completely blocked by G3 and G4 phosphorous dendrimers (Figure 6b). As can be observed, these data strongly suggest ER stress and UPR response as possible targets for this direct neuroprotective action of neutral phosphorous dendrimers.




Figure 5. Effect of phosphorous dendrimers on NMDA-induced changes in ER-stress-signaling proteins and in caspase 12 activity. (a) Neurons were treated with vehicle (V) or the indicated concentration of G3 or G4 phosphorous dendrimers for 1 h. Then, NMDA (150 μ M) was added and the incubation continued for another 1 h for p-eIF2 α and eIF2 α determination and for 6 h for Bip, ATF4, and Chop protein determination by Western blot, as described in the Materials and Methods section. α -Tubulin was used as loading control. The image shows one representative experiment that was repeated three times with similar results. (b) Neurons were treated with vehicle (V) or the indicated concentration of phosphorous dendrimers for 1 h. Then, NMDA (150 μ M) was added and after 6 h, caspase 12 activity measured as indicated in the Methods section. The data represent the mean + the s.e.m. of three experiments. *** $p < 0.001$ as compared to NMDA-treated cells in the absence of dendrimers.




Figure 6. Cont.




Figure 6. Quantification of the effect of phosphorous dendrimers on NMDA-induced changes in ER stress proteins. Neurons were treated with vehicle (V) or with 10 μ M of G3 or G4 phosphorous dendrimers for 1 h. Then, NMDA (150 μ M) was added and incubation continued for another 1 h for (a) p-eiF2 α and eiF2 α determination and for 6 h for (b) Bip and (c) ATF4 determination. α -Tubulin was used as loading control. The data are expressed as the mean + the s.e.m. of three experiments. ** $p < 0.01$ as compared to NMDA-treated cells in the absence of dendrimers.

2.6. Phosphorous Dendrimers Inhibit NMDA-Induced Excitotoxicity in Brain Organoids

Exposure of brain organoids to NMDA (150 μ M; 24 h) induced the death of about 5% of the brain organoid neurons, this effect being markedly decreased by treatment of the organoids with G4 phosphorus dendrimers (10 μ M) (Figure 7).




Figure 7. Phosphorous dendrimers prevent NMDA-mediated excitotoxicity in human brain organoids. Brain organoids were treated with either vehicle (V) or G4 phosphorous dendrimers (10 μ M) for 1 h, and then NMDA (150 μ M) was added and incubation continued for another 24 h. LDH was determined as indicated in the Materials and Methods section. The data represent the mean \pm the s.e.m. of six experiments. ** $p < 0.01$ when compared to NMDA-treated neurons in the absence of dendrimers.

In addition, the treatment of brain organoids with NMDA (150 μ M; 24 h) induced a marked increase in caspases 9 (Figure 8a) and 3 (Figure 8b) enzymatic activities, suggesting activation of the intrinsic apoptotic pathway. Treatment of the organoid with G4 phosphorous dendrimer did not show any toxic effect. However, it markedly blocked NMDA-induced caspase activation in a similar way to the effect found in isolated cultured mouse cortical neurons (Figure 8a,b). NMDA also induced an increase in caspase 12 activity, suggesting the involvement of the ER stress response (Figure 8c). This activation was also decreased in the presence of G4 phosphorous dendrimers (Figure 8c).




Figure 8. Effect of the phosphorous dendrimer G4 on NMDA-induced (a) caspase 9, (b) caspase 3, and (c) caspase 12 enzymatic activity in brain organoids. Brain organoids were treated with either vehicle (V) or G4 phosphorous dendrimer (10 μ M) for 1 h, and then NMDA (150 μ M) was added. Caspase 3 and 9 activities were determined at 3 h and caspase 12 at 6 h. Caspase activity was determined in total lysates as described in the Materials and Methods section. The data are expressed as the mean + the s.e.m. of five independent experiments. ** $p < 0.01$, *** $p < 0.001$ as compared to NMDA-treated cells in the absence of dendrimers.

3. Discussion

Nanoparticles are becoming increasingly involved in therapeutics as drug and genetic material delivery systems [2,3]. This is due to the fact that they can be synthesized with a high degree of control of the structural parameters, yielding highly monodisperse chemical structures [34]. However, nanoparticles can themselves show therapeutic properties in the absence of other added drugs or genetic material [12]. Dendrimers are a polymeric type of nanoparticles that have a promising role in therapeutics [14]. Among the different types of dendrimers, phosphorous dendrimers possess interesting properties for imaging, the delivery of nucleic acids or drugs, and as drugs by themselves. Cationic phosphorous dendrimers have shown activity against scrapie, preventing protein aggregation of prions, responsible for the development of transmissible spongiform encephalopathies [13]. Moreover, neutral phosphorous dendrimers present anti-inflammatory properties both in vitro and in vivo [12].

Excitotoxicity plays a key role in the pathogenesis of several CNS diseases, including stroke [35] and Alzheimer's [36] and Parkinson's [37] diseases. Excitotoxicity is caused by over-stimulation by glutamate of ionotropic receptors NMDA, α -amino-3-hydroxy-5-methyl-4-isoxazolpropionic acid (AMPA), and Kainate [23]. Excessive activation of the ionotropic receptors, mainly NMDAR, induces a massive Ca^{2+} influx into the cells, leading to neuronal death in the CNS [38]. Besides intensive research efforts, no effective treatment is available for these diseases yet, indicating the need for new therapeutic agents.

Excitotoxicity-induced increase in $[\text{Ca}^{2+}]_i$ leads to mitochondrial dysfunction, an increase in ROS, and activation of several proinflammatory molecules, including NF- κ B, which causes neuroinflammation. All these mechanisms contribute to neurodegeneration [39]. Since the aza-bisphosphonate-terminated neutral phosphorous dendrimers used

in this work have shown anti-inflammatory properties both in vitro and in vivo by preventing NF- κ B translocation to the cell nucleus [12], and neuroinflammation has been proposed as one of the possible mechanisms contributing to the pathogenesis of Alzheimer's disease [40], we decided to study whether these neutral phosphorous dendrimers were able to inhibit neuronal excitotoxic death.

The phosphorous dendrimers did not interfere with NMDA-mediated Ca^{2+} influx since $[\text{Ca}^{2+}]_i$ in response to NMDA were similar in the presence and absence of phosphorous dendrimers. This excludes the fact that the nanoparticles will behave as NMDA receptor blockers and strongly suggests an intracellular mechanism of action, which has an important implication: neutral phosphorous dendrimers are able to gain access to the neuron interior, which is quite uncommon for an NP. This opens up a wide range of possibilities for their use in therapeutics of nervous system diseases.

Marked Ca^{2+} influx following NMDAR stimulation leads to mitochondrial Ca^{2+} overload, which results in the formation of a non-selective pore across the mitochondrial membrane, known as the mitochondrial permeability transition pore [41]. The pore collapses Ψ_m ; increases ROS production [42]; and promotes the release of pro-apoptotic molecules; such as cytochrome c and Apaf-1 [43], which, in turn, will sequentially activate caspases 9 and 3, the latter being an executioner caspase whose activation results in cellular apoptosis [44]. Both G3 and G4 phosphorous dendrimers significantly inhibit NMDA-induced Ψ_m collapse and ROS production, both locally in the mitochondria and in the whole neuron, and induction of caspase 9 and 3 activities. However, antioxidant compounds have shown neuroprotection in vitro [45,46] and one possible mechanism involved in the neuroprotective action of phosphorous dendrimers on NMDA-mediated excitotoxicity could be to interfere with ROS production in a step beyond Ψ_m in addition to their action diminishing NMDA-mediated Ψ_m collapse. This does not seem to be the case, since in cell-free systems or in cortical neurons or brain organoid lysates, neither did phosphorous dendrimers show any effect on xanthine oxidase enzymatic activity nor did they act as a ROS scavenging compound, while the SOD mimetic MnTABP, used as the control, did. These results suggest that one of the possible mechanisms involved in the neuroprotective action of neutral phosphorous dendrimers might be to interfere with NMDA-induced Ψ_m collapse and thus with the intrinsic-apoptotic-signaling pathway.

However, Ca^{2+} buffering is one of the processes that link mitochondria and ER functions through the formation of functional structures called mitochondrial-associated membranes [47]. The connection between ER and mitochondria regulates ATP production, mitochondrial dynamics, lipid biosynthesis, and cell survival [48]. Therefore, mitochondrial dysfunction triggered by excitotoxicity could also alter ER function, leading to UPR activation. In fact, we have shown that NMDA-induced activation of the ER stress response was characterized by a rapid increase in the phosphorylation of eIF2 α , which was followed by the up-regulation of the chaperonin GRP-78/Bip, ATF4, and CHOP. It is noteworthy that ATF4 and its downstream target, CHOP, are both transcription factors involved in ER-stress-induced apoptosis [49]. An increase in caspase 12 activity was also detected at later times, suggesting that it might also contribute to NMDA-induced neuronal death [50]. Thus, it would be possible that another target for phosphorous dendrimers to inhibit NMDA-mediated excitotoxic death was ER stress. This is the case since both G3 and G4 phosphorous dendrimers were able to completely block eIF2 α phosphorylation and to partially inhibit ER-stress-induced expression of Bip and ATF4 as well as caspase 12 activity.

Brain organoids represent a marked step forward in terms of transability of basic research results to the clinical setting for several diseases, including neurodegenerative diseases. Organoids recapitulate several of the characteristics of the human brain, such as 3D organization achieved through self-organization of the developing organoids, making them an attractive model for the human brain by maintaining mechanical and cellular topographical relationships that generate close-to-physiological microenvironments [51]. This makes them more useful in providing information about the effect of possible therapeutic compounds on the specific human-pathogenic-signaling cascades involved in neuronal

death than two-dimensional neuronal culture or animal models of neurologic disease [52]. Here, we show that NMDA induces excitotoxic death in human brain organoids. It is important to note that the percentage of NMDA-induced neuronal death, as indicated by the release of LDH to the medium, is markedly lower in the case of brain organoids than for isolated cultured mouse neurons. This indicates the more complex nature of brain organoids comprising different cell types, many of them lacking NMDA receptors, as it happens in the human brain, and also a complex tridimensional organization, while isolated cultured neurons constitute a homogeneous cell population containing NMDA receptors. Moreover, NMDA induced, in brain organoids, an increase in the activity of caspases 3 and 9, biochemical markers of the intrinsic apoptotic pathway. In addition, NMDA induced an increase in caspase 12 activity, which occurs mainly in response to ER stress. These data indicate that NMDA activates in the brain organoid the same mechanisms of excitotoxic death as it does in cultured neurons. It is important to note that G4-biocompatible bisphosphonate-terminated neutral phosphorous dendrimers were able to markedly reduce these deleterious actions of NMDA in brain organoids, indicating that the dendrimer not only is able to penetrate the 3D structure of the brain organoid to reach the cortical plate area but also faithfully reproduces its pharmacological actions on NMDA-induced excitotoxic death observed in primary neuronal cultures.

4. Materials and Methods

4.1. Chemical Synthesis

The synthesis of phosphorous dendrimers, generations 3 and 4, bearing 48 and 96 terminal bisphosphonate groups, respectively, was performed as previously described [12].

4.2. Animals

All experimental procedures were conducted and animal care performed in accordance with the guidelines of the Ethical Committee of Animal Experimentation (CEEA), which issued the proper permit (protocol number PR-2017-07-18, approved July 18, 2017) at the University of Castilla-La Mancha (UCLM), in accordance with the guidelines of the European Union (2010/63/EU) for the use of laboratory animals, and the ARRIVE guidelines were followed for experiments involving animals [53].

4.3. Cell Culture

Primary cultures of brain cortical neurons were obtained as previously described [54]. Briefly, fronto-lateral cortical lobes from E17 C57BL/6 mice fetuses were dissected and the cells were chemically dissociated in the presence of trypsin and DNase I. The isolated cells were resuspended in serum-free Neurobasal[®] medium supplemented with B27 containing penicillin (20 units mL⁻¹), streptomycin (5 µg mL⁻¹), and 2 µM L-glutamine. Cells were plated on poly-L-lysine-coated 24- or 6-well culture plates or on poly-L-lysine-coated glass coverslips and maintained at 37 °C in a saturated atmosphere containing 95% air and 5% CO₂. Cortical neurons were used for experiments after being cultured for 7–12 days in vitro (DIV).

4.4. Brain Organoids

Brain organoids were generated following the procedure previously described [15]. Briefly, human pluripotent stem cells (PSCs; ATCC, Barcelona, Spain) were allowed to generate embryonic bodies that were induced to differentiate to neural tissue in a medium with low content of b Fibroblast Growth Factor (bFGF) and a high concentration of Rho-associated coiled-coil containing protein kinases (ROCK) inhibitor. Embryonic bodies were placed in Matrigel and allowed to generate a properly oriented neuroepithelium and self-organized 3D structure under continuous agitation as previously described [55].

4.5. Cellular Toxicity

At DIV 7–12, cortical neurons were treated with either vehicle (double-distilled water; ddH₂O) or NMDA (150 μ M) in the absence or presence of G3 or G4 phosphorous dendrimers at different concentrations. Twenty-four hours later, supernatants were collected and the cells washed with phosphate-buffered saline (PBS) and lysed with 0.9% Triton X-100 (V/V) in saline. Lactate dehydrogenase (LDH) activity release to the culture medium was used as an indicator of cellular death [56]. LDH release to the medium as well as that present in the cell lysates were determined using the Cytotox 96 Kit (Promega, Madison, WI, USA) following the manufacturer's instructions. Cell mortality was expressed as the percentage of LDH released with respect to the total LDH content in the cells at the beginning of treatment.

4.6. Intracellular Ca²⁺ Measurement

Cytosolic Ca²⁺ was determined as previously described [11]. Cortical neurons (DIV 7–12) were seeded on poly-L-lysine-coated glass coverslips (20 mm) and treated with either vehicle or G3 or G4 phosphorous dendrimers (10 μ M; 1 h). Afterward, cells were incubated in Krebs–Henseleit (K–H) solution with the ionic composition (in mM) NaCl, 140; CaCl₂, 2.5; MgCl₂, 1; KCl, 5; HEPES, 5; and Glucose, 11 (pH, 7.4) solution containing Fura-2 (5 μ M) and 0.005% (v/v) Pluronic (Thermo Fisher, Madrid, Spain) for 30 min at 37 °C in the dark. Coverslips were washed twice with K–H solution and mounted on the stage of a Nikon Eclipse TE2000-E fluorescence microscope (Nikon, Tokyo, Japan). The cells were excited alternately at 340 nm and 380 nm and emitted fluorescence recorded at 510 nm using a CCD camera (Hamamatsu Photonics, Shizuoka, Japan), at 200 Hz sampling rate, using the NIS Elements AR software (Nikon, Tokyo, Japan). Basal [Ca²⁺]_i was obtained for the initial 39 s, and then NMDA (150 μ M) was added and frames recorded for 60 additional seconds.

4.7. ROS Generation

Cortical neurons (DIV 7–12) were treated with vehicle or NMDA (150 μ M) in the absence or presence of G3 or G4 phosphorous dendrimers at the indicated concentrations for different lengths of time. Afterward, the cells were incubated in K–H solution containing the ROS-sensitive fluorescent dye chloro-methyl 2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA 10 μ M; Molecular Probes, Barcelona, Spain) or with the mitochondrial-specific superoxide-sensitive fluorescent dye MitoSOX Red (2.5 μ M; Invitrogen, Carlsbad, CA, USA) for 30 min at 37 °C. After being washed twice with K–H solution, the coverslips were placed on the stage of a Nikon Eclipse TE2000-E fluorescence microscope (Nikon, Tokyo, Japan). Excitation and emission wavelengths were set at 535 nm and 635 nm for H2DCFDA fluorescence and 510 nm and 580 nm for MitoSOX Red, respectively. Samples were recorded every 15 s using a CCD camera (Hamamatsu Photonics, Shizuoka, Japan) and analyzed using the NIS Elements AR software (Nikon, Tokyo, Japan). Recorded fluorescence for each experimental condition was fitted to the equation $y = a + bx$, and the slope b was taken as an index of the rate of superoxide production as previously described [57].

4.8. Mitochondrial Transmembrane Potential

The mitochondrial transmembrane potential (Ψ_m) was determined as previously described [58]. Briefly, cortical neurons (DIV 7–12) were treated with either vehicle or NMDA (150 μ M) in the absence or presence of G3 or G4 phosphorous dendrimers at the indicated concentrations for different lengths of time. Afterward, the cells were incubated in K–H solution containing tetramethylrhodamine methyl ester (10 μ M; TMRM) (Thermo Fisher, Madrid, Spain), washed with K–H solution, and mounted on the stage of a Nikon Eclipse TE2000-E fluorescence microscope (Nikon, Tokyo, Japan). The cells were excited at 535 nm wavelength and emitted fluorescence recorded at 590 nm using the NIS Elements AR software (Nikon, Tokyo, Japan). Samples were recorded every 15 s for 5 min with a CCD camera (Hamamatsu Photonics, Shizuoka, Japan). Decaying fluorescence signal showing

mitochondrial potential was fitted using a linear regression model and the least squares method. The slopes of the fitted lines were taken as the rate of loss of Ψ_m . Percentages of Ψ_m loss rates were calculated with respect to vehicle-treated cells.

4.9. Extraction of Total Lysates

Cortical neurons (DIV 7-12) were treated with either or NMDA (150 μ M) in the absence or presence of G3 or G4 phosphorous dendrimers at the indicated concentrations for different lengths of time. Afterward, the cells were washed twice with cold PBS and resuspended in homogenization buffer (10 mM Hepes, 0.32 M sucrose, 100 μ M EDTA, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 40 μ g mL⁻¹ aprotinine, and 20 μ g mL⁻¹ leupeptine; pH 7.4). Cortical neurons were homogenized using a polytron (two cycles; 10 s at maximum speed). Afterward, the homogenates were centrifuged at 10,000 \times g and supernatants (i.e., total lysates) collected and stored at -80 °C until analysis by gel electrophoresis or caspase activity determination was performed.

4.10. Caspase Activities Determination

Caspase 3, caspase 9, and caspase 12 activities were determined in total lysates as previously described [56]. Briefly, fluorescent substrates Z-Asp-Glu-Val-Asp-7-Amino-4-trifluoromethylcoumarin (Z-DEVD-AFC), Ac-Leu-Glu-His-Asp-7-Amino-4-trifluoromethyl coumarin (Ac-LEHD-AFC), and Ac-Ala-Thr-Ala-Asp-7-Amino-4-trifluoromethylcoumarin (Ac-ATAD-AFC) were used to determine caspase 3, 9, and 12 activities, respectively. Lysates (50 μ g of protein) were incubated at 37 °C for 1 h following the manufacturer's instructions (BioVision, Milpitas, CA, USA). Cleavage of the AFC fluorophore was determined in a spectrofluorometer (Victor3; Perkin Elmer, Madrid, Spain) at an excitation wavelength of 400 nm and at an emission wavelength of 505 nm. Caspase activities were calculated as units of fluorescence formed per milligram of protein per hour.

4.11. Western Blot Assay

Immunoblot analysis was performed on total lysates as previously described [54]. Protein samples from total lysates (25 μ g) were loaded onto 10% or 15% PAGE-SDS gels and transferred to nitrocellulose membranes. Membranes were blocked in PBS-Tween 20 (0.1%) containing 5% non-fat dry milk and 0.1% BSA for 1 h at 4 °C and incubated with primary antibodies directed against the protein of interest overnight at 4 °C. The primary antibodies used were rabbit monoclonal anti-eIF2 α antibody (1:1000), rabbit monoclonal anti-peIF2 α antibody (1:1000), rabbit monoclonal anti-Bip antibody (1:1000), and rabbit monoclonal anti-ATF4 antibody (1:1000), all of them obtained from Cell Signaling (Leiden, The Netherlands); mouse monoclonal anti-CHOP antibody (1:1000) (RD systems, Minneapolis, MN, USA); and mouse polyclonal α -tubulin antibody (1:2000) (Calbiochem, Barcelona, Spain). Afterward, the membranes were washed and incubated with the corresponding secondary antibody HRP anti-rabbit IgG (1:10,000) or HRP anti-mouse IgG (1:10,000). Immunoreactive bands were visualized using an enhanced chemiluminescence system (ECL, Amersham BiosciencesGE Healthcare, Uppsala, Sweden). Densitometric analysis of immunoreactive bands was performed using ImageQuant 5.2 software (GE Healthcare, Uppsala, Sweden).

5. Conclusions

In summary, both G3- and G4-biocompatible bisphosphonate-terminated neutral phosphorus dendrimers showed strong neuroprotective actions against NMDA-induced excitotoxic neuronal death in primary neuronal cultures. These actions are not related to the inhibition of NMDA-mediated Ca²⁺ influx but to an intracellular mechanism of action. It is important to note that it is not easy for NPs, either alone or carrying a cargo, to enter the neurons. These two phosphorous dendrimers are one of the few examples of NPs entering primary neuronal cultures, which opens a wide range of possibilities to use these NPs to study neuronal physiology and pathophysiology. In addition, these neutral phosphorous dendrimers can interfere with excitotoxic mechanisms at two different levels:

preventing Ψ m collapse and reducing the UPR response that follows ER stress. Moreover, these phosphorous dendrimers can penetrate human brain organoids, where they can interfere with NMDA-induced mechanisms of neuronal death in a similar way as they do in isolated neuronal cultures, indicating the ability of the dendrimers to penetrate complex tridimensional structures, such as brain organoid structures, which replicate a significant number of properties of the human brain. Taken together, these actions, combined with the anti-inflammatory properties previously shown in vivo and in vitro [12], strongly suggest that these NPs have the potential to be used as scaffolds to generate new macromolecules as compounds that might be effective for neurodegenerative diseases treatment. This approach might open new avenues for the treatment of neurodegenerative diseases.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms23084391/s1>. Reference [59] is cited in Supplementary Materials.

Author Contributions: Conceptualization, I.P., M.M.-F. and V.C.; methodology, I.P., L.R.-C., R.-A.R. and A.K.; validation, M.M.-F. and V.C.; formal analysis, I.P., S.M., J.-P.M., M.M.-F. and V.C.; investigation, I.P., L.R.-C., R.-A.R. and A.K.; resources, I.P., S.M., J.-P.M., M.M.-F. and V.C.; writing—original draft preparation, I.P.; writing—review and editing, M.M.-F. and V.C.; supervision, V.C.; project administration, V.C.; funding acquisition, I.P., S.M., J.-P.M., M.M.-F. and V.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1), the Spanish Ministerio de Ciencia e Innovación (project PID2020-120134RB-I00 from MINECO/AEI/FEDER/UE) to V.C.; from Instituto de Salud Carlos III (ISCIII; projects RETIC PT17/0015/0042, PI19/01638) to M.M.-F.; from Junta de Comunidades de Castilla-La Mancha (project SBPLY/19/180501/000067) to V.C. and I.P.; ISCIII and ERANET Euronanomed Program (project NANO4GLIO) to V.C. and J.-P.M.; and Action Nano2Clinic (CA17140), supported by COST (European Cooperation in Science and Technology), to V.C. and M.M.-F. J.-P.M. and A.K. thank CNRS for financial support. S.M. acknowledges the support of FCT-Fundação para a Ciência e a Tecnologia (Base Fund UIDB/00674/2020 and Programmatic Fund UIDP/00674/2020, Portuguese Government Funds) and ARDITI-Agência Regional para o Desenvolvimento da Investigação Tecnologia e Inovação through the project M1420-01-0145-FEDER-000005-CQM+ (Madeira 14-20 Program).

Institutional Review Board Statement: The animal study protocol was approved by the Ethical Committee of Animal Experimentation (CEEAA), which issued the proper permit (protocol number PR-2017-07-18) at the University of Castilla-La Mancha (UCLM), in accordance with the guidelines of the European Union (2010/63/EU) for the use of laboratory animals and followed the ARRIVE guidelines for experiments involving animals.

Informed Consent Statement: Not applicable.

Data Availability Statement: The manuscript data can be made available from the corresponding author following reasonable request.

Acknowledgments: The authors acknowledge the excellent technical support from Vanesa Guijarro and M^a Jesús Serramía.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wang, Y.; Li, S.; Wang, X.; Chen, Q.; He, Z.; Luo, C.; Sun, J. Smart transformable nanomedicines for cancer therapy. *Biomaterials* **2021**, *271*, 120737. [[CrossRef](#)] [[PubMed](#)]
2. Adams, D.; Gonzalez-Duarte, A.; O’Riordan, W.D.; Yang, C.C.; Ueda, M.; Kristen, A.V.; Tournev, I.; Schmidt, H.H.; Coelho, T.; Berk, J.L.; et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *N. Engl. J. Med.* **2018**, *379*, 11–21. [[CrossRef](#)] [[PubMed](#)]
3. Balwani, M.; Sardh, E.; Ventura, P.; Peiro, P.A.; Rees, D.C.; Stolzel, U.; Bissell, D.M.; Bonkovsky, H.L.; Windyga, J.; Anderson, K.E.; et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. *N. Engl. J. Med.* **2020**, *382*, 2289–2301. [[CrossRef](#)] [[PubMed](#)]
4. Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update post COVID-19 vaccines. *Bioeng. Transl. Med.* **2021**, *6*, e10246. [[CrossRef](#)]

5. Global Burden Disease Dementia 2016. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **2019**, *18*, 88–106. [[CrossRef](#)]
6. Cena, V.; Jativa, P. Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases. *Nanomedicine* **2018**, *13*, 1513–1516. [[CrossRef](#)]
7. Chouhan, R.S.; Horvat, M.; Ahmed, J.; Alhokbany, N.; Alshehri, S.M.; Gandhi, S. Magnetic Nanoparticles-A Multifunctional Potential Agent for Diagnosis and Therapy. *Cancers* **2021**, *13*, 2213. [[CrossRef](#)]
8. Kashapov, R.; Ibragimova, A.; Pavlov, R.; Gabdrakhmanov, D.; Kashapova, N.; Burilova, E.; Zakharova, L.; Sinyashin, O. Nanocarriers for Biomedicine: From Lipid Formulations to Inorganic and Hybrid Nanoparticles. *Int. J. Mol. Sci.* **2021**, *22*, 7055. [[CrossRef](#)]
9. Tomalia, D.A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A New Class of Polymers-Starburst-Dendritic Macromolecules. *Polym. J.* **1985**, *17*, 117–132. [[CrossRef](#)]
10. Zhong, D.; Wu, H.; Wu, Y.; Li, Y.; Yang, J.; Gong, Q.; Luo, K.; Gu, Z. Redox dual-responsive dendrimeric nanoparticles for mutually synergistic chemo-photodynamic therapy to overcome drug resistance. *J. Control. Release* **2021**, *329*, 1210–1221. [[CrossRef](#)]
11. Posadas, I.; Perez-Martinez, F.C.; Guerra, J.; Sanchez-Verdu, P.; Ceña, V. Cofilin activation mediates Bax translocation to mitochondria during excitotoxic neuronal death. *J. Neurochem.* **2012**, *120*, 515–527. [[CrossRef](#)] [[PubMed](#)]
12. Posadas, I.; Romero-Castillo, L.; El, B.N.; Manzanares, D.; Mignani, S.; Majoral, J.P.; Ceña, V. Neutral high-generation phosphorus dendrimers inhibit macrophage-mediated inflammatory response in vitro and in vivo. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E7660–E7669. [[CrossRef](#)] [[PubMed](#)]
13. Solassol, J.; Crozet, C.; Perrier, V.; Leclaire, J.; Beranger, F.; Caminade, A.M.; Meunier, B.; Dormont, D.; Majoral, J.P.; Lehmann, S. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. *J. Gen. Virol.* **2004**, *85*, 1791–1799. [[CrossRef](#)] [[PubMed](#)]
14. Mignani, S.; Rodrigues, J.; Roy, R.; Shi, X.; Cena, V.; El Kazzouli, S.; Majoral, J.P. Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2). *Drug Discov. Today* **2019**, *24*, 1184–1192. [[CrossRef](#)] [[PubMed](#)]
15. Lancaster, M.A.; Knoblich, J.A. Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science* **2014**, *345*, 1247125. [[CrossRef](#)]
16. Huch, M.; Koo, B.K. Modeling mouse and human development using organoid cultures. *Development* **2015**, *142*, 3113–3125. [[CrossRef](#)]
17. Corro, C.; Novellademunt, L.; Li, V.S.W. A brief history of organoids. *Am. J. Physiol. Cell Physiol.* **2020**, *319*, C151–C165. [[CrossRef](#)]
18. Mansour, A.A.; Schafer, S.T.; Gage, F.H. Cellular complexity in brain organoids: Current progress and unsolved issues. *Semin. Cell Dev. Biol.* **2021**, *111*, 32–39. [[CrossRef](#)]
19. Chen, H.I.; Song, H.; Ming, G.L. Applications of Human Brain Organoids to Clinical Problems. *Dev. Dyn.* **2019**, *248*, 53–64. [[CrossRef](#)]
20. Joffe, M.E.; Santiago, C.I.; Stansley, B.J.; Maksymetz, J.; Gogliotti, R.G.; Engers, J.L.; Nicoletti, F.; Lindsley, C.W.; Conn, P.J. Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress. *Neuropharmacology* **2019**, *144*, 19–28. [[CrossRef](#)]
21. Maiolino, M.; O'Neill, N.; Lariccia, V.; Amoroso, S.; Sylantyev, S.; Angelova, P.R.; Abramov, A.Y. Inorganic Polyphosphate Regulates AMPA and NMDA Receptors and Protects Against Glutamate Excitotoxicity via Activation of P2Y Receptors. *J. Neurosci.* **2019**, *39*, 6038–6048. [[CrossRef](#)] [[PubMed](#)]
22. Mira, R.G.; Cerpa, W. Building a Bridge Between NMDAR-Mediated Excitotoxicity and Mitochondrial Dysfunction in Chronic and Acute Diseases. *Cell Mol. Neurobiol.* **2020**, *41*, 1413–1430. [[CrossRef](#)] [[PubMed](#)]
23. Wroge, C.M.; Hogins, J.; Eisenman, L.; Mennerick, S. Synaptic NMDA receptors mediate hypoxic excitotoxic death. *J. Neurosci.* **2012**, *32*, 6732–6742. [[CrossRef](#)] [[PubMed](#)]
24. Briston, T.; Hicks, A.R. Mitochondrial dysfunction and neurodegenerative proteinopathies: Mechanisms and prospects for therapeutic intervention. *Biochem. Soc. Trans.* **2018**, *46*, 829–842. [[CrossRef](#)] [[PubMed](#)]
25. Mekahli, D.; Bultynck, G.; Parys, J.B.; De Smedt, H.; Missiaen, L. Endoplasmic-reticulum calcium depletion and disease. *Cold Spring Harb. Perspect. Biol.* **2011**, *3*, a004317. [[CrossRef](#)] [[PubMed](#)]
26. Arduino, D.M.; Esteves, A.R.; Cardoso, S.M.; Oliveira, C.R. Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: Relevance to Parkinson's disease. *Neurochem. Int.* **2009**, *55*, 341–348. [[CrossRef](#)]
27. Almanza, A.; Carlesso, A.; Chintha, C.; Creedican, S.; Doultinos, D.; Leuzzi, B.; Luis, A.; McCarthy, N.; Montibeller, L.; More, S.; et al. Endoplasmic reticulum stress signalling—From basic mechanisms to clinical applications. *FEBS J.* **2019**, *286*, 241–278. [[CrossRef](#)]
28. Marciniak, S.J.; Ron, D. Endoplasmic reticulum stress signaling in disease. *Physiol. Rev.* **2006**, *86*, 1133–1149. [[CrossRef](#)]
29. Ruiz, A.; Matute, C.; Alberdi, E. Endoplasmic reticulum Ca(2+) release through ryanodine and IP(3) receptors contributes to neuronal excitotoxicity. *Cell Calcium.* **2009**, *46*, 273–281. [[CrossRef](#)]
30. Chamorro, A.; Dirnagl, U.; Urra, X.; Planas, A.M. Neuroprotection in acute stroke: Targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. *Lancet Neurol.* **2016**, *15*, 869–881. [[CrossRef](#)]
31. Choi, D.W. Excitotoxic cell death. *J. Neurobiol.* **1992**, *23*, 1261–1276. [[CrossRef](#)] [[PubMed](#)]

32. Luetjens, C.M.; Bui, N.T.; Sengpiel, B.; Munstermann, G.; Poppe, M.; Krohn, A.J.; Bauerbach, E.; Kriegelstein, J.; Prehn, J.H. Delayed mitochondrial dysfunction in excitotoxic neuron death: Cytochrome c release and a secondary increase in superoxide production. *J. Neurosci.* **2000**, *20*, 5715–5723. [[CrossRef](#)] [[PubMed](#)]
33. Ankarcrona, M.; Dypbukt, J.M.; Bonfoco, E.; Zhivotovsky, B.; Orrenius, S.; Lipton, S.A.; Nicotera, P. Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. *Neuron* **1995**, *15*, 961–973. [[CrossRef](#)]
34. Mignani, S.; Shi, X.; Ceña, V.; Shcharbin, D.; Bryszewska, M.; Majoral, J.P. In vivo therapeutic applications of phosphorus dendrimers: State of the art. *Drug Discov. Today* **2021**, *26*, 677–689. [[CrossRef](#)] [[PubMed](#)]
35. Choi, D.W. Excitotoxicity: Still Hammering the Ischemic Brain in 2020. *Front. Neurosci.* **2020**, *14*, 579953. [[CrossRef](#)] [[PubMed](#)]
36. Zadori, D.; Veres, G.; Szalardy, L.; Klivenyi, P.; Vecsei, L. Alzheimer’s Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenes. *J. Alzheimers Dis.* **2018**, *62*, 523–547. [[CrossRef](#)]
37. Wang, J.; Wang, F.; Mai, D.; Qu, S. Molecular Mechanisms of Glutamate Toxicity in Parkinson’s Disease. *Front. Neurosci.* **2020**, *14*, 585584. [[CrossRef](#)]
38. Lipton, S.A.; Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. *N. Engl. J. Med.* **1994**, *330*, 613–622.
39. Lindsay, A.; Hickman, D.; Srinivasan, M. A nuclear factor-kappa B inhibiting peptide suppresses innate immune receptors and gliosis in a transgenic mouse model of Alzheimer’s disease. *Biomed. Pharmacother.* **2021**, *138*, 111405. [[CrossRef](#)]
40. Maccioni, R.B.; Navarrete, L.P.; Gonzalez, A.; Gonzalez-Canacer, A.; Guzman-Martinez, L.; Cortes, N. Inflammation: A Major Target for Compounds to Control Alzheimer’s Disease. *J. Alzheimers Dis.* **2020**, *76*, 1199–1213. [[CrossRef](#)]
41. Chinopoulos, C. Mitochondrial permeability transition pore: Back to the drawing board. *Neurochem. Int.* **2018**, *117*, 49–54. [[CrossRef](#)] [[PubMed](#)]
42. Schinder, A.F.; Olson, E.C.; Spitzer, N.C.; Montal, M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. *J. Neurosci.* **1996**, *16*, 6125–6133. [[CrossRef](#)] [[PubMed](#)]
43. Polster, B.M.; Fiskum, G. Mitochondrial mechanisms of neural cell apoptosis. *J. Neurochem.* **2004**, *90*, 1281–1289. [[CrossRef](#)] [[PubMed](#)]
44. Jelinek, M.; Balusikova, K.; Schmiedlova, M.; Nemcova-Furstova, V.; Sramek, J.; Stancikova, J.; Zanardi, I.; Ojima, I.; Kovar, J. The role of individual caspases in cell death induction by taxanes in breast cancer cells. *Cancer Cell Int.* **2015**, *15*, 8. [[CrossRef](#)] [[PubMed](#)]
45. Gottlieb, M.; Leal-Campanario, R.; Campos-Esparza, M.R.; Sanchez-Gomez, M.V.; Alberdi, E.; Arranz, A.; Delgado-Garcia, J.M.; Gruart, A.; Matute, C. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. *Neurobiol. Dis.* **2006**, *23*, 374–386. [[CrossRef](#)] [[PubMed](#)]
46. Malik, I.; Shah, F.A.; Ali, T.; Tan, Z.; Alattar, A.; Ullah, N.; Khan, A.U.; Alshaman, R.; Li, S. Potent Natural Antioxidant Carveol Attenuates MCAO-Stress Induced Oxidative, Neurodegeneration by Regulating the Nrf-2 Pathway. *Front. Neurosci.* **2020**, *14*, 659. [[CrossRef](#)] [[PubMed](#)]
47. Herrando-Grabulosa, M.; Gaja-Capdevila, N.; Vela, J.M.; Navarro, X. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. *Br. J. Pharmacol.* **2021**, *178*, 1336–1352. [[CrossRef](#)]
48. Marchi, S.; Bittremieux, M.; Missiroli, S.; Morganti, C.; Paternani, S.; Sbrana, L.; Rimessi, A.; Kerkhofs, M.; Parys, J.B.; Bultynck, G.; et al. Endoplasmic Reticulum-Mitochondria Communication Through Ca(2+) Signaling: The Importance of Mitochondria-Associated Membranes (MAMs). *Adv. Exp. Med. Biol.* **2017**, *997*, 49–67.
49. Galehdar, Z.; Swan, P.; Fuerth, B.; Callaghan, S.M.; Park, D.S.; Cregan, S.P. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. *J. Neurosci.* **2010**, *30*, 16938–16948. [[CrossRef](#)]
50. Pan, C.; Prentice, H.; Price, A.L.; Wu, J.Y. Beneficial effect of taurine on hypoxia- and glutamate-induced endoplasmic reticulum stress pathways in primary neuronal culture. *Amino Acids* **2012**, *43*, 845–855. [[CrossRef](#)]
51. Lancaster, M.A.; Renner, M.; Martin, C.A.; Wenzel, D.; Bicknell, L.S.; Hurles, M.E.; Homfray, T.; Penninger, J.M.; Jackson, A.P.; Knoblich, J.A. Cerebral organoids model human brain development and microcephaly. *Nature* **2013**, *501*, 373–379. [[CrossRef](#)] [[PubMed](#)]
52. Bang, S.; Lee, S.; Choi, N.; Kim, H.N. Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. *Adv. Healthc. Mater.* **2021**, *10*, e2002119. [[CrossRef](#)] [[PubMed](#)]
53. McGrath, J.C.; Drummond, G.B.; McLachlan, E.M.; Kilkenny, C.; Wainwright, C.L. Guidelines for reporting experiments involving animals: The ARRIVE guidelines. *Br. J. Pharmacol.* **2010**, *160*, 1573–1576. [[CrossRef](#)] [[PubMed](#)]
54. Perez-Carrion, M.D.; Perez-Martinez, F.C.; Merino, S.; Sanchez-Verdu, P.; Martinez-Hernandez, J.; Lujan, R.; Ceña, V. Dendrimer-mediated siRNA delivery knocks down Beclin 1 and potentiates NMDA-mediated toxicity in rat cortical neurons. *J. Neurochem.* **2012**, *120*, 259–268. [[CrossRef](#)]
55. Wang, Y.; Wang, L.; Zhu, Y.; Qin, J. Human brain organoid-on-a-chip to model prenatal nicotine exposure. *Lab Chip* **2018**, *18*, 851–860. [[CrossRef](#)]
56. Lopez-Hernandez, B.; Posadas, I.; Podlesniy, P.; Abad, M.A.; Trullas, R.; Ceña, V. HIF-1alpha is neuroprotective during the early phases of mild hypoxia in rat cortical neurons. *Exp. Neurol.* **2012**, *233*, 543–554. [[CrossRef](#)]
57. Posadas, I.; Santos, P.; Blanco, A.; Muñoz-Fernandez, M.; Ceña, V. Acetaminophen induces apoptosis in rat cortical neurons. *PLoS ONE* **2010**, *5*, e15360. [[CrossRef](#)]

58. Posadas, I.; Vellecco, V.; Santos, P.; Prieto-Lloret, J.; Ceña, V. Acetaminophen potentiates staurosporine-induced death in a human neuroblastoma cell line. *Br. J. Pharmacol.* **2007**, *150*, 577–585. [[CrossRef](#)]
59. Liu, X.; Chen, R.; Shang, Y.; Jiao, B.; Huang, C. Superoxide radicals scavenging and xanthine oxidase inhibitory activity of magnesium lithospermate B from *Salvia miltiorrhiza*. *J. Enzym. Inhib. Med. Chem.* **2008**, *24*, 663–668. [[CrossRef](#)]